| ds-analogy-0071fb6d | Cross-disease analogy hypothesis: does the mechanism transfer? [cva-21ecbe1b170b | 0.00 | 0 | 3 | pending | 2026-04-28 | |
| ds-analogy-07d0d4f0 | Cross-disease analogy hypothesis: does the mechanism transfer? [cva-ca8efa5251c7 | 0.00 | 0 | 3 | pending | 2026-04-28 | |
| ds-analogy-83f16d1c | Cross-disease analogy hypothesis: does the mechanism transfer? [cva-a54efa09cf07 | 0.00 | 0 | 3 | pending | 2026-04-28 | |
| ds-analogy-fac64406 | Cross-disease analogy hypothesis: does the mechanism transfer? [cva-18b1df861e39 | 0.00 | 0 | 3 | pending | 2026-04-28 | |
| ds-analogy-16052934 | Cross-disease analogy hypothesis: does the mechanism transfer? [cva-e503e171657c | 0.00 | 0 | 3 | pending | 2026-04-28 | |
| sess_SDA-TEST-PREREG | Test question for preregistration | 0.77 | 7 | 4 | completed | 2026-04-28 | SDA-TEST-PREREG-003 |
| sess_SDA-2026-04-27- | Methodology challenge: notebook 'Astrocyte reactivity subtypes in neurodegenerat | 0.64 | 3 | 4 | completed | 2026-04-28 | SDA-2026-04-27-gap-methodol-20260427-035148-9ab1842d |
| sess_SDA-2026-04-27- | Methodology challenge: notebook 'Mitochondrial transfer between neurons and glia | 0.64 | 3 | 4 | completed | 2026-04-28 | SDA-2026-04-27-gap-methodol-20260427-035148-7b3b3df4 |
| sess_AD-MASTER-PLAN- | TREM2 enhancement reduces microglial dysfunction and downstream tau pathology, s | 0.64 | 3 | 4 | completed | 2026-04-28 | AD-MASTER-PLAN-TREM2-20260428030753 |
| sess_AD-MASTER-PLAN- | APOE4-driven lipid dysregulation and synaptic phagocytosis drive AD; converting | 0.64 | 3 | 4 | completed | 2026-04-28 | AD-MASTER-PLAN-APOE-20260428030754 |
| sess_AD-MASTER-PLAN- | BDNF-mediated hippocampal synaptic rescue restores CA3-CA1 connectivity and prev | 0.64 | 3 | 4 | completed | 2026-04-28 | AD-MASTER-PLAN-BDNF-20260428030755 |
| sess_AD-MASTER-PLAN- | GFAP-positive reactive astrocytes mediate regional vulnerability through dysfunc | 0.64 | 3 | 4 | completed | 2026-04-28 | AD-MASTER-PLAN-GFAP-20260428030756 |
| sess_AD-MASTER-PLAN- | LRP1-mediated tau uptake disruption in neurons initiates the earliest tau propag | 0.64 | 3 | 4 | completed | 2026-04-28 | AD-MASTER-PLAN-LRP1-20260428030757 |
| sess_SDA-2026-04-28- | Is microglial priming (TREM2/CX3CR1/complement-C1q) genuinely causally upstream | 0.64 | 3 | 4 | completed | 2026-04-28 | SDA-2026-04-28-microglial-priming-causal-nd |
| sess_SDA-causal-benc | How does SciDEX's debate-engine compare to other LLM methods for causal discover | 0.64 | 3 | 4 | completed | 2026-04-28 | SDA-causal-benchmark-20260428-035713 |
| sess_SDA-2026-04-28- | Methodology challenge: notebook 'Mitochondrial transfer between neurons and glia | 0.64 | 3 | 4 | completed | 2026-04-28 | SDA-2026-04-28-gap-methodol-20260427-035148-7b3b3df4 |
| sess_8f05a068-5b1e-4 | How do APOE4-driven lipid droplet and cholesterol-metabolism differences in micr | 0.76 | 1 | 4 | completed | 2026-04-28 | 8f05a068-5b1e-4f32-8ca9-2f375b5dbaf3 |
| sess_52661eaf-79f8-4 | What are the biophysical determinants — RNA binding stoichiometry, post-translat | 0.67 | 3 | 4 | completed | 2026-04-28 | 52661eaf-79f8-4647-8f48-3389f5af4d59 |
| sess_687fb884-6d31-4 | What are the relative contributions of cell-autonomous motor neuron mechanisms v | 0.67 | 3 | 4 | completed | 2026-04-28 | 687fb884-6d31-47c3-a83f-074bad980db6 |
| sess_db9a224d-3ebb-4 | Which non-neuronal cell types (astrocytes, oligodendrocytes, pericytes) exhibit | 0.67 | 3 | 4 | completed | 2026-04-28 | db9a224d-3ebb-429c-8f02-b703d71ca211 |
| sess_b7f886d9-da3f-4 | How does N6-methyladenosine (m6A) RNA modification alter alpha-synuclein mRNA st | 0.67 | 3 | 4 | completed | 2026-04-28 | b7f886d9-da3f-4e0d-a8a8-9c262e268796 |
| sess_f7f8019f-08f6-4 | How does the CCL2-CCR2 chemokine axis at the neuromuscular junction drive select | 0.67 | 3 | 4 | completed | 2026-04-28 | f7f8019f-08f6-428b-adff-85e8ea202b60 |
| sess_0ed3c364-07fd-4 | What is the precise causal sequence of molecular events linking TDP-43 nuclear c | 0.67 | 3 | 4 | completed | 2026-04-28 | 0ed3c364-07fd-4620-8e90-8bd33c14e370 |
| sess_bf5094c7-8ae0-4 | Do PD-associated genetic aging landscape variants causally accelerate epigenetic | 0.67 | 3 | 4 | completed | 2026-04-28 | bf5094c7-8ae0-4331-9871-d6f3078387c5 |
| sess_8ec36980-febb-4 | Which proteogenomic network hubs identified by multi-omics PD studies are drugga | 0.67 | 3 | 4 | completed | 2026-04-28 | 8ec36980-febb-4093-a5a1-387ea5768480 |
| sess_a7f528aa-20c4-4 | How do VEGF family gene variants identified by single-cell GWAS analysis alter c | 0.67 | 3 | 4 | completed | 2026-04-28 | a7f528aa-20c4-409d-a8c3-e2662850e63d |
| sess_457c5bc3-21d8-4 | What cell-type-specific gene regulatory networks mediate the DPP6 GWAS signal fo | 0.67 | 3 | 4 | completed | 2026-04-28 | 457c5bc3-21d8-42a3-bb99-b0fc6f3f9554 |
| sess_dfb32151-9c40-4 | What sex-specific microglial transcriptional states emerge in response to amyloi | 0.67 | 3 | 4 | completed | 2026-04-28 | dfb32151-9c40-452d-8063-0c57bae5c3d6 |
| sess_ana_f07c10cf-7e | Can targeting oxidative stress pathways (NRF2, SOD1, mitochondrial ROS) upstream | 0.62 | 0 | 6 | completed | 2026-04-28 | f07c10cf-7e5a-4a02-9479-327aa5c963b5 |
| sess_ana_26866808-a2 | How do GWAS-identified PD risk variants at the LRRK2 locus alter lysosomal membr | 0.89 | 0 | 6 | completed | 2026-04-28 | 26866808-a2cf-4e6e-976d-bc900aef6e0a |
| sess_ana_0847737b-b8 | What spatially resolved cell-cell communication networks between oligodendrocyte | 0.83 | 0 | 6 | completed | 2026-04-28 | 0847737b-b8f3-4130-b8c2-65015add1117 |
| ds-target-d9e2b8db2a | Should neuronal identity transcription factors be prioritized as therapeutic tar | 0.72 | 0 | 3 | completed | 2026-04-28 | |
| sess_ext_h-2600483e_ | Extended debate: CYP46A1 Overexpression Gene Therapy | 0.95 | 0 | 6 | completed | 2026-04-28 | SDA-2026-04-01-gap-lipid-rafts-2026-04-01 |
| sess_ext_SDA-2026-04 | Extended debate: Metabolic Reprogramming to Reverse Senescence | 0.95 | 0 | 6 | completed | 2026-04-28 | SDA-2026-04-04-gap-senescent-clearance-neuro |
| sess_ext_h-var-de167 | Extended debate: TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegenera | 0.95 | 0 | 6 | completed | 2026-04-28 | SDA-2026-04-26-trem2-showcase |
| sess_ext_h-var-58e76 | Extended debate: Closed-loop transcranial focused ultrasound with 40Hz gamma ent | 0.95 | 0 | 6 | completed | 2026-04-28 | SDA-2026-04-03-26abc5e5f9f2 |
| sess_ext_h-var-3b982 | Extended debate: Closed-loop tACS targeting EC-II SST interneurons to block tau | 0.95 | 0 | 6 | completed | 2026-04-28 | SDA-2026-04-03-26abc5e5f9f2 |
| pan_e0f8efc0 | are LLMs conscious? | 0.00 | 0 | 0 | completed | 2026-04-28 | |
| pan_f11f02fc | Is the amyloid cascade hypothesis still the best explanation for AD? | 0.50 | 0 | 0 | completed | 2026-04-27 | |
| test-chamber-session | test question | 0.50 | 0 | 0 | completed | 2026-04-27 | |
| pan_f3022c8f | Is the amyloid cascade hypothesis still the best explanation for AD? | 0.50 | 0 | 0 | completed | 2026-04-27 | |
| test-chamber-session | test question | 0.50 | 0 | 0 | completed | 2026-04-27 | |
| test-debate-1ba85200 | Does APOE4 drive tau propagation via mitochondrial dysfunction? | 0.75 | 0 | 0 | completed | 2026-04-27 | |
| test-debate-7bf87108 | Does APOE4 drive tau propagation via mitochondrial dysfunction? | 0.75 | 0 | 0 | completed | 2026-04-27 | |
| pan_46017aa0 | smoke - what is the strongest evidence against the amyloid cascade | 0.50 | 0 | 0 | completed | 2026-04-27 | |
| pan_01105bdc | what is the root cause of alzheimer's | 0.50 | 0 | 0 | completed | 2026-04-27 | |
| pan_41ec088e | smoke - what is the strongest evidence against the amyloid cascade | 0.50 | 0 | 0 | completed | 2026-04-27 | |
| pan_b2789997 | smoke - what is the strongest evidence against the amyloid cascade | 0.50 | 0 | 0 | completed | 2026-04-27 | |
| pan_af7f06b2 | smoke | 0.50 | 0 | 0 | completed | 2026-04-27 | |
| pan_853885a7 | smoke - what is the strongest evidence against the amyloid cascade hypothesis | 0.50 | 0 | 0 | completed | 2026-04-27 | |